SurGenTec

SurGenTec is a private medical device company dedicated to pushing the technology in the spine and orthopedic industries to new heights. SurGenTec considers the safety of both patients and doctors when developing and producing innovative products. They currently have a variety of products on the market, sold domestically in the United States and internationally. In 2018, SurGenTec's ALARA™ Target Needle System received the Spine Technology Award at the NASS (North American Spine Society) conference in Los Angeles, California, USA. On August 26, 2020, their proprietary OsteoFlo NanoPutty- Quadphasic patent received 510(k) clearance from the U.S. Food and Drug Administration (FDA). OsteoFlo NanoPutty is a novel bone graft solution featuring the world’s first and only synthetic bone graft granules with quad-phasic properties utilizing nanosurface technology. OsteoFlo NanoPutty is designed to provide an optimal resorption profile with unparalleled handling characteristics.